Conference News
From the Journals

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Share

  • 1

    Adagrasib and cetuximab combination therapy showed promising outcomes in metastatic KRAS G12C-mutated colorectal cancer patients.

  • 2

    The objective response rate in the KRYSTAL-1 trial was 34% and the disease control rate was 85.1%.

  • 3

    Responses to the combination therapy lasted a median of 5.8 months.

  • 4

    The therapy is currently under Priority Review by the U.S. FDA and being evaluated in the phase III KRYSTAL-10 trial.

  • 5

    Lead study author is Scott Kopetz, MD, PhD, from MD Anderson Cancer Center.

Original Source(s)

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

  • by Conexiant News Staff

  • May 2, 2024

  • 2 min

Related Content

Income, BMI Linked to Colon Capsule Completion

Danish screening data identify clinical and socioeconomic factors that significantly influence whether colon capsule exams are completed.

Biomarkers Expand Precision in CRC

Emerging biomarkers guide colorectal cancer diagnosis, stratification, and treatment selection

New NCI Grant to Foster Development of Novel Therapy in Metastatic Colorectal Cancer

The Case Western Reserve University School of Medicine received a 5-year $1.84 million grant to investigate the role of the LRG1 protein in colorectal cancer growth and develop a novel treatment option for patients with metastatic colorectal cancer.